Leerink Partners and Evercore ISI are acting as joint bookrunning managers for the offering. LifeSci Capital is also acting as a bookrunning manager in the offering. Citizens Capital Markets and ...

First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 Strengthened Leadership Team with the ...

As of March 31, 2025, Aura had cash and cash equivalents and marketable securities totaling $128.0 million. The Company believes its current cash and cash equivalents and marketable securities are ...

Blue Light Cystoscopy with Cysview utilizes a special scope and dye to detect and treat non muscle invasive bladder cancer.

In the 10-Q report, CG Oncology reported a net loss of $34.5 million for the three months ended March 31, 2025, compared to a ...

Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...

Q1 2025 Earnings Call Transcript May 12, 2025 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Q1 2025 Earnings Call Transcript May 12, 2025 UroGen Pharma Ltd. misses on earnings expectations. Reported EPS is $-0.92 EPS, ...

The approval in MIBC was based on positive results from the phase 3 NIAGARA trial, in which the Imfinzi regimen demonstrated ...

Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 st ...

Detailed price information for Artara Therapeutics Inc (TARA-Q) from The Globe and Mail including charting and trades.

High-risk NMIBC is characterised by poor prognosis, with half of patients recurring despite effective treatment with the ...